COMP Recommends CTI-1601 as Orphan Drug for Treating Friedreich’s Ataxia

Print Friendly, PDF & Email

RE: FRIEDREICH’S ATAXIA: The Committee for Orphan Medicinal Products (COMP), an arm of the European Medicines Agency (EMA), has issued a positive opinion about granting orphan drug status to CTI-1601 , Larimar Therapeutics’ investigational treatment for Friedreich’s ataxia (FA). The company now is expecting the European Commission , which makes the final […]